Daclizumab (Ro 24-7375) is a humanized, monoclonal antibody that blocks CD25 (alpha-subunit of the high-affinity interleukin-2 receptor (IL-2R-HA)). Daclizumab inhibits effector T cell activation, regulatory T cell (Treg) expansion and survival, and activation-induced T-cell apoptosis. Daclizumab increases IL-2 bioavailability to bind to the intermediate-affinity IL-2R (IL-2R-IA), driving the expansion of anti-inflammatory CD56bright natural killer (NK) cells. Daclizumab can be used for multiple sclerosis and cancer research[1].
Molekulargewicht:
(144.24 kDa)
Reinheit:
99.18
CAS Nummer:
[152923-56-3]
Target-Kategorie:
Apoptosis,Interleukin Related
Anwendungsbeschreibung:
MCE Product type: Inhibitory Antibodies
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten
